All In Biotech

Drug Trial Radar · NCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,314 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,314

Planned (sponsor's estimate)

Start

Dec 18, 2023

Primary completion

May 10, 2028

Study completion Dec 2, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to overall survival (OS), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Prostatic Neoplasms

Interventions

  • OpevesostatDrug

    Administered orally

  • DexamethasoneDrug

    Administered orally

  • Fludrocortisone acetateDrug

    Administered orally

  • HydrocortisoneDrug

    Administered orally or IM as a rescue drug

  • Abiraterone acetateDrug

    Administered orally

  • Prednisone acetateDrug

    Administered orally

  • EnzalutamideDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 82 months

Locations

330 sites in 39 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center - North Campus ( Site 0073)

    Tucson, Arizona · Recruiting

  • CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 0120)

    Irvine, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica ( Site 0044)

    Los Angeles, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)

    Orange, California · Recruiting

  • Stanford Cancer Center ( Site 0036)

    Palo Alto, California · Recruiting

  • Emad Ibrahim,MD,INC. ( Site 0012)

    Redlands, California · Completed

  • Kaiser Permanente Riverside Medical Center ( Site 0099)

    Riverside, California · Recruiting

  • University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 0114)

    Sacramento, California · Recruiting

  • San Francisco VA Health Care System ( Site 0093)

    San Francisco, California · Recruiting

  • Kaiser Permanente-Kaiser Permanente, Vallejo Medical Center, Adult Oncology ( Site 0101)

    Vallejo, California · Active not recruiting

  • University of Colorado Anschutz Medical Campus ( Site 0046)

    Aurora, Colorado · Recruiting

  • UCHealth Highlands Ranch Hospital ( Site 0111)

    Highlands Ranch, Colorado · Recruiting

  • Colorado Clinical Research ( Site 0067)

    Lakewood, Colorado · Recruiting

  • University of Colorado Health - Lone Tree Medical Center ( Site 0112)

    Lone Tree, Colorado · Recruiting

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)

    New Haven, Connecticut · Recruiting

  • MedStar Washington Hospital Center ( Site 0103)

    Washington D.C., District of Columbia · Recruiting

  • Florida Cancer Specialists - South ( Site 7003)

    Fort Myers, Florida · Active not recruiting

  • Mount Sinai Braman Comprehensive Cancer Center ( Site 0107)

    Miami Beach, Florida · Recruiting

  • Memorial Hospital West-Memorial Cancer Institute ( Site 0109)

    Pembroke Pines, Florida · Recruiting

  • Northside Hospital-Northside Hospital Oncology Network ( Site 0100)

    Atlanta, Georgia · Recruiting

  • Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0074)

    Elmhurst, Illinois · Completed

  • Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075)

    Naperville, Illinois · Completed

  • Illinois Cancer Care ( Site 0104)

    Peoria, Illinois · Recruiting

  • Urology of Indiana - Carmel ( Site 0055)

    Carmel, Indiana · Recruiting

  • University of Kentucky Chandler Medical Center ( Site 0048)

    Lexington, Kentucky · Active not recruiting

  • Baltimore Veterans Affairs Medical Center ( Site 0069)

    Baltimore, Maryland · Recruiting

  • Greenebaum Comprehensive Cancer Center ( Site 0049)

    Baltimore, Maryland · Recruiting

  • Chesapeake Urology ( Site 0009)

    Towson, Maryland · Recruiting

  • Henry Ford Hospital ( Site 0015)

    Detroit, Michigan · Recruiting

  • Cancer and Hematology Centers of Western Michigan ( Site 0005)

    Grand Rapids, Michigan · Recruiting

  • Avera Cancer Institute - Marshall ( Site 0122)

    Marshall, Minnesota · Recruiting

  • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0072)

    Saint Louis Park, Minnesota · Recruiting

  • HealthPartners Cancer Research Center-HealthPartners Cancer Center at Regions Hospital ( Site 0092)

    Saint Paul, Minnesota · Recruiting

  • St. Vincent Frontier Cancer Center-Research ( Site 0037)

    Billings, Montana · Recruiting

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026)

    Omaha, Nebraska · Recruiting

  • OptumCare Cancer Care-Research Department ( Site 0078)

    Las Vegas, Nevada · Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 0010)

    Las Vegas, Nevada · Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 0033)

    New Brunswick, New Jersey · Recruiting

  • Associated Medical Professionals - Urology ( Site 0081)

    Syracuse, New York · Recruiting

  • University Hospitals Cleveland Medical Center ( Site 0043)

    Cleveland, Ohio · Recruiting

Showing 40 of 330 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.